Literature DB >> 29427071

Response to 'Comment on ''Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy"'.

Amir Ansaripour1, Carin A Uyl-de Groot2, W Ken Redekop2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29427071     DOI: 10.1007/s40273-018-0620-y

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  3 in total

1.  From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare.

Authors:  Matthijs Versteegh; Saskia Knies; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

2.  Optimality, Future and Terminal Costs: Comment on "Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran".

Authors:  Noga Gershon; Yakir Berchenko
Journal:  Pharmacoeconomics       Date:  2018-03       Impact factor: 4.981

3.  Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy.

Authors:  Amir Ansaripour; Carin A Uyl-de Groot; W Ken Redekop
Journal:  Pharmacoeconomics       Date:  2018-01       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.